ProQR Therapeutics’ (PRQR) “Overweight” Rating Reaffirmed at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of ProQR Therapeutics (NASDAQ:PRQR) in a report released on Friday morning,Benzinga reports. Cantor Fitzgerald currently has a $8.00 target price on the biopharmaceutical company’s stock.

A number of other equities analysts have also recently issued reports on the stock. Citigroup raised shares of ProQR Therapeutics from a “neutral” rating to a “buy” rating and set a $4.00 price objective on the stock in a research note on Monday, March 10th. JMP Securities reaffirmed a “market outperform” rating and issued a $8.00 price objective on shares of ProQR Therapeutics in a research note on Friday. HC Wainwright lifted their price target on shares of ProQR Therapeutics from $10.00 to $12.00 and gave the stock a “buy” rating in a research report on Friday, March 14th. Chardan Capital reissued a “buy” rating and set a $4.00 price target on shares of ProQR Therapeutics in a research report on Friday, March 14th. Finally, Evercore ISI started coverage on shares of ProQR Therapeutics in a research report on Tuesday, April 29th. They set an “outperform” rating and a $5.00 price target on the stock. One research analyst has rated the stock with a sell rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $8.00.

ProQR Therapeutics Stock Performance

Shares of PRQR stock opened at $2.04 on Friday. ProQR Therapeutics has a 52-week low of $1.07 and a 52-week high of $4.62. The stock has a market cap of $214.63 million, a PE ratio of -5.83 and a beta of 0.31. The firm’s 50 day moving average price is $1.72 and its two-hundred day moving average price is $1.98.

ProQR Therapeutics (NASDAQ:PRQR) last announced its quarterly earnings data on Thursday, May 8th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). ProQR Therapeutics had a negative net margin of 157.04% and a negative return on equity of 53.49%. The business had revenue of $4.89 million during the quarter, compared to the consensus estimate of $4.90 million. As a group, sell-side analysts predict that ProQR Therapeutics will post -0.31 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ProQR Therapeutics

Several institutional investors have recently added to or reduced their stakes in PRQR. M&T Bank Corp bought a new stake in ProQR Therapeutics in the 4th quarter valued at $330,000. Raymond James Financial Inc. bought a new stake in ProQR Therapeutics in the 4th quarter valued at $260,000. PNC Financial Services Group Inc. bought a new stake in ProQR Therapeutics in the 4th quarter valued at $77,000. Platinum Investment Management Ltd. bought a new stake in ProQR Therapeutics in the 4th quarter valued at $4,076,000. Finally, Virtu Financial LLC bought a new stake in ProQR Therapeutics in the 4th quarter valued at $83,000. 32.65% of the stock is owned by institutional investors.

About ProQR Therapeutics

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).